- [Resource Hub](/) - [Publication](/?resource-type=publication#library) - The Spatial Landscape of Progression and Immunoediting in Primary Melanoma at Single-Cell Resolution # The Spatial Landscape of Progression and Immunoediting in Primary Melanoma at Single-Cell Resolution Nirmal AJ, Maliga Z, Vallius T, Quattrochi B, Chen AA, Jacobson CA, et al. Cancer Discovery . 2022;12(6):1518-1541. DOI [10.1158/2159-8290.CD-21-1357](https://doi.org/10.1158/2159-8290.CD-21-1357). PMID 35404441. PMCID PMC9167783. How to cite ### AMA Nirmal AJ, Maliga Z, Vallius T, Quattrochi B, Chen AA, Jacobson CA, et al. The Spatial Landscape of Progression and Immunoediting in Primary Melanoma at Single-Cell Resolution. Cancer Discov . 2022;12(6):1518-1541. doi:10.1158/2159-8290.CD-21-1357 ### APA Nirmal, A. J., Maliga, Z., Vallius, T., Quattrochi, B., Chen, A. A., Jacobson, C. A., et al. (2022). The Spatial Landscape of Progression and Immunoediting in Primary Melanoma at Single-Cell Resolution. Cancer Discovery , 12(6), 1518-1541. https://doi.org/10.1158/2159-8290.CD-21-1357 ### BibTeX @article{nirmal2022spatial, title = {The Spatial Landscape of Progression and Immunoediting in Primary Melanoma at Single-Cell Resolution}, author = {Nirmal, Ajit J. and Maliga, Zoltan and Vallius, Tuulia and Quattrochi, Brian and Chen, Alyce A. and Jacobson, Connor A. and others}, journal = {Cancer Discovery}, volume = {12}, number = {6}, pages = {1518--1541}, year = {2022}, doi = {10.1158/2159-8290.CD-21-1357}, pmid = {35404441} } Primary melanoma is usually caught early and removed, but some tumors progress from a thin, curable lesion to an invasive, dangerous one. Pathologists grade these stages by eye on stained tissue, yet what actually changes in the tumor and its surrounding immune cells as melanoma advances has been hard to see cell by cell. The authors built a spatial, single-cell map of 13 primary melanomas that each contained several progression stages in one specimen. Using high-plex whole-slide imaging, they tracked how tumor cells and immune cells rearrange from precursor lesions through invasive disease, and found layered immune-suppressive barriers concentrated at the tumor's invasive front. [Read publication at Cancer Discovery](https://pmc.ncbi.nlm.nih.gov/articles/PMC9167783/) ## Key findings - Thirteen primary melanomas, each spanning several progression stages, were mapped at single-cell resolution. Serial FFPE sections were imaged by whole-slide 20- to 30-plex cyclic immunofluorescence (CyCIF), with 70 annotated regions of interest analyzed across the cohort. - Roughly 70% of cytotoxic T cells expressed the activation marker PD1, but very few tumor cells expressed PDL1. The authors concluded that myeloid cells, not tumor cells, are the predominant source of PDL1 engaging PD1-positive T cells at the invasive front. - The invasive front carried at least six overlapping immune-suppressive mechanisms operating within a few millimeters of one another. These ranged from PD1–PDL1 cell contacts to tumor-intrinsic MHC-II and IDO1 expression, with active immunoediting found within millimeters of near-complete immune exclusion. ## CyteFinder in the methods “Images were acquired using a CyteFinder slide scanning fluorescence microscope (RareCyte Inc.) with a 20×/0.75 NA objective.” — Nirmal et al., Cancer Discovery (2022), Methods, “Imaging (H&E and Tissue-Based CyCIF)” Disclosure: RareCyte is named in the competing-interests statement of the publication cited above. ## Why it matters for CyteFinder users If you are considering the CyteFinder for a tissue-imaging program, this melanoma atlas shows what it carries at scale. The study's argument is spatial: to see how melanoma progresses, the authors imaged whole slides rather than small cores, because the features that matter — where cytotoxic T cells engage tumor cells, how immune suppression concentrates at the invasive front — only resolve across an entire section. They ran 20- to 30-plex cyclic immunofluorescence on thirteen primary melanomas, acquiring every staining cycle on the CyteFinder and stitching the cycles into whole-slide, single-cell images that span multiple progression stages in one specimen. The same instrument then did double duty: its integrated CytePicker module physically retrieved 40-micron tissue microregions for downstream transcriptomics, so imaging and molecular sampling came from the same annotated tissue. For your own work the point is direct: when the biology lives across a whole specimen, the CyteFinder is the instrument that both images it and picks from it. [Back to all resources](/#library) ## Related resources [Article](https://www.selectscience.net/product-news/measuring-versus-reading-transforming-the-field-of-quantitative-pathology?artid=58733) CyteFinder SelectScience ### Measuring versus reading – transforming the field of quantitative pathology [Read Article](https://www.selectscience.net/product-news/measuring-versus-reading-transforming-the-field-of-quantitative-pathology?artid=58733) [Spec Sheet](https://go.pardot.com/l/455452/2019-11-18/7mzyyz/455452/220141/TS20_103.pdf) CyteFinder ### CyteFinder II HT [View Spec Sheet](https://go.pardot.com/l/455452/2019-11-18/7mzyyz/455452/220141/TS20_103.pdf) [Spec Sheet](https://go.pardot.com/l/455452/2019-11-18/7mzyz2/455452/220143/TS20_104.pdf) CyteFinder ### CyteFinder II [View Spec Sheet](https://go.pardot.com/l/455452/2019-11-18/7mzyz2/455452/220143/TS20_104.pdf) [Publication](https://doi.org/10.1200/JCO.2026.44.16_suppl.5041) CyteFinder Journal of Clinical Oncology 2026 ### Clinical validation of circulating tumor cell synaptophysin and androgen receptor expression in metastatic prostate cancer phenotypes. [View Publication](https://doi.org/10.1200/JCO.2026.44.16_suppl.5041) [Video](https://www.youtube.com/watch?v=_oGC1KRVN2U) CyteFinder 2026 ### Dr. Pashtoon Kasi on the impact of circulating tumor cells on clinical research [Watch Video](https://www.youtube.com/watch?v=_oGC1KRVN2U) [Publication](https://doi.org/10.1038/s41587-026-03099-z) CyteFinder Nature Biotechnology 2026 ### mRNA vaccine immunity is enhanced by hepatocyte detargeting and not dependent on dendritic cell expression [View Publication](https://doi.org/10.1038/s41587-026-03099-z) [Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC7618831/) CyteFinder Cancer Immunology Research 2026 ### Ex Vivo Immuno-Oncology Platform Reveals Spatial T Cell Infiltration Patterns Linked to ATR Inhibition Responses in High-Grade Serous Ovarian Cancer [View Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC7618831/) [Publication](https://doi.org/10.1097/pai.0000000000001311) CyteFinder Applied Immunohistochemistry & Molecular Morphology 2026 ### Quantitative Assays for TROP2 Measurement in Breast Cancer and Comparison to H-Score [View Publication](https://doi.org/10.1097/pai.0000000000001311) [Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC12881594/) CyteFinder Nature Communications 2026 ### Extracellular matrix mediates circulating tumor cell clustering in triple-negative breast cancer metastasis [View Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC12881594/) [Publication](https://doi.org/10.1016/j.ejso.2025.111357) CyteFinder European Journal of Surgical Oncology 2026 ### Circulating tumor cells predict relapse in head and neck mucosal squamous cell carcinoma [View Publication](https://doi.org/10.1016/j.ejso.2025.111357) [Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC12805936/) CyteFinder Cancer Research Communications 2026 ### Surface Marker Identification to Capture Live Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer [View Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC12805936/) [Publication](https://doi.org/10.1158/1078-0432.CCR-25-0244) CyteFinder Clinical Cancer Research 2025 ### Pre-clinical Modeling of Navtemadlin Pharmacokinetics, Pharmacodynamics, and Efficacy in IDH-wildtype Glioblastoma [View Publication](https://doi.org/10.1158/1078-0432.CCR-25-0244)